1/16/24
When receiving advanced therapies, biologically female individuals with psoriatic arthritis are less likely to achieve desired treatment outcomes compared to biologically male individuals, suggests a recent study published in The Lancet Rheumatology.
The study aimed to compare the effectiveness of advanced therapies (such as biologics and targeted synthetic treatments) in male and female patients with psoriatic arthritis. They did this by analyzing the results of 54 previously published randomized controlled trials. The authors of the study searched various databases and conference archives for relevant trials, and then they analyzed data on response rates to treatment, broken down by sex.
Of the 54 trials included in the study, only 18 reported results by sex. The researchers found that at the start of the trials, men generally had lower joint pain and tenderness, but higher levels of psoriasis and inflammation markers, compared to women. When looking at different types of advanced therapies, men had better response rates to IL-17 and TNF inhibitors compared to women. However, there were no significant differences between men and women for JAK and TYK2 inhibitors.
Overall, the results suggest that the biological sex of patients can influence their response to advanced therapies, but more research is needed to determine the extent of that influence. The authors of the study emphasize that future psoriatic arthritis trials should report results by sex so that researchers can better understand these sex-related differences.
References:
Input your search keywords and press Enter.
